MAM
Rahul Karwa joins Geometry Encompass as COO – west
MUMBAI: Geometry Encompass, India’s leading experiential marketing and brand activation agency, a part of WPP, recently appointed Rahul Karwa as their Chief Operating Officer (COO) – West. He will operate out of the Mumbai office.
In the past, he has worked with the agency in the capacity of Managing Partner. During his last assignment at Geometry Encompass he took up the responsibility of setting up a new-age activation agency called Engage at Encompass. Within the short span of one year, Engage became the fastest growing strategic business unit within the Geometry Global Encompass Network (GGNE) and soon after, established Encompass as a leading Activation Specialist for clients.
With over 19 years of experience, Rahul has worked with numerous companies and media agencies. Before rejoining Geometry Encompass he headed The Bucketlist, a full-service experiential marketing agency, as the Chief Executive Officer. In his previous stints, he has worked as a specialist Rural Marketer at Ogilvy Action, as Brand Head at DDB MudraMax (Experiential Marketing, West) and Senior Vice President at WPP. He has also worked as Planner at Reliance Capital (2007-2008).
On joining Geometry Encompass, Rahul said, “I am happy to be able to come back to Geometry Encompass, in many ways it’s almost like coming back home. In my new role, I hope to support the agency in its growth journey and to drive operational excellence across the portfolio of services. I look forward to leading this team of innovative disruptors.”
Welcoming Karwa aboard, Roshan Abbas, Founder and Managing Director, Geometry Encompass said, “In our attempt to build the agency of the future we are always on the search for new talent and sometimes we find people who have been on a journey with us before. Rahul has delivered exceptional results in the past while leading Engage. Now that he has rejoined us in this journey, I believe we are now stronger than ever. I welcome him aboard.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
